Expression Of CCNG2 In Gliomas And Relationship Between CCNG2 Expression And Chemotherapy

Gliomas, benign and malignant centra system neoplasms derived from glial cells, are the common intracranial tumor. Although diagnosis and treatment have advanced over the past decades, patients with gliomas are still with a poor prognosis, which is due to the fact that the mechanism of the disease has not been fully elucidated.Cyclin G2 (CCNG2) gene belongs to the cyclins "G" family. Previous data showed that as a key negative regulator of cell cycle progression, this gene may contribute to the regulation of cell proliferation, apoptosis, cell death signaling, even and carcinogenesis. However the role of CCNG2 in glioma carcinogenesis is still unknown, even there still are few reports about the expression and roles of CCNG2 protein in patients with gliomas.In this paper, in order to explore the possible roles of CCNG2 in clinical progression of gliomas, we for the first time investigated the expression of CCNG2 in gliomas from low-to high-grades and the correlation with clinicopathological features and overall survival of 105 patients with gliomas. We found that the expression level of CCNG2 was correlated with the WHO grades and with the survival time of patients with gliomas. In addition, we increased the expression of CCNG2 in U251 glioma cell lines, and investigated the effects of CCNG2 on the sensitivity of glioma to chemotherapeutic agents in vitro.The paper is consisted of two parts:Partâ… CCNG2 expression in human gliomas:clinical significance in pathological grade and overall patient survivalObjective:The study characterized the expression of CCNG2 in tissues of human gliomas, and investigated its clinical significance in patients with gliomas. Methods:Tissue specimens were collected from 105 Chinese patients undergoing surgical resection for glioma. The expression of CCNG2 in these specimens was examined by real-time quantitative PCR and immunohistochemistry.Results:PCR and IHC showed the mRNA and protein level of CCNG2 was significantly associated with glioma histopathology (WHO grading). CCNG2 was expressed in the glioma specimens with cytoplasmic staining. Of the 71 cases of astrocytic tumours patients, loss of CCNG2 expression correlated significantly with poor overall survival time in univariate and multivariate analyses. Conclusions:CCNG2 expression decreased significantly as disease stage advanced and prognosis worsen, suggesting that CCNG2 may play important roles as a negative regulator to glioma development and progression. CCNG2 might be a useful molecular marker for predicting the prognosis of high-grade glioma.